Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 7, 2011, Pages 1131-1137

  Mury, Dina ^a   Woelber, Linn ^a   Jung, Sabine ^a   Eulenburg, Christine ^a   Choschzick, Matthias ^a   Witzel, Isabell ^a   Schwarz, Joerg ^a,b   Jaenicke, Fritz ^a   Mahner, Sven ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Asklepios Clinic   (Germany)

Author keywords

CA 125; Ovarian cancer; Prognosis; Survival; Three dimensional waterfall plot

Indexed keywords

CA 125 ANTIGEN;

ADULT; ADVANCED CANCER; AGED; APPENDECTOMY; ARTICLE; BLOOD LEVEL; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; EARLY CANCER; FEMALE; HUMAN; HYSTERECTOMY; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OMENTECTOMY; OVARY CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 79959763418     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-0977-1     Document Type: Article

References (29)

1. Barlow TS, Przybylski M, Schilder JM, Moore DH, Look KY (2006) The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer 16(2):496-500
2. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68(5):1331-1337 (Pubitemid 12235035)
3. Bast RC Jr, Klug TL, St. John E, Jenison E, NiloV JM, Lazarus H, Berkowitz RS, Leavitt T, GriYths CT, Parker L, Zurawski VR Jr, Knapp RC (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309(15):883-887 (Pubitemid 13014028)
4. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15(3):274-281 (Pubitemid 43096594)
5. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, Montz FJ (2000) A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89(7):1532-1540
6. Cannistra SA, Bast RC Jr, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP 3rd, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L (2003) Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol 21(10):129s-132s
7. Chi DS, Venkatraman ES, Masson V, Hoskins WJ (2000) The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77(2):227-231 (Pubitemid 30317140)
8. Colombo PE, Mourregot A, Fabbro M, Gutowski M, Saint-Aubert B, Quenet F, Gourgou S, Rouanet P (2009) Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol 35(2):135-143
9. Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE (2002) Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 100(1):59-64 (Pubitemid 34722843)
10. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, PWsterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115(6):1234-1244
11. Geisler JP, Miller GA, Lee TH, Harwood RM, Wiemann MC, Geisler HE (1996) Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma. J Reprod Med 41(3):140-142 (Pubitemid 26087657)
12. Guppy AE, Rustin GJ (2002) CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 7(5):437-443
13. IARC IAfRoC (2006) Descriptive epidemiology group of IARC Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P (2007) CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically deWned disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 104(1):176-180
14. Kang S, Kim TJ, Nam BH, Seo SS, Kim BG, Bae DS, Park SY (2010) Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol 101(1):13-17
15. Kumar P, Rehani MM, Kumar L, Sharma R, Bhatla N, Chaudhry R, Thulkar S, Sundaram KR, Kumar N (2005) Tumor marker CA- 125 as an evaluator and response indicator in ovarian cancer: its quantitative correlation with tumor volume. Med Sci Monit 11(2):CR84-CR89
16. Lloyd KO, Yin BW, Kudryashov V (1997) Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identiWcation as a mucin-type molecule. Int J Cancer 71(5):842-850 (Pubitemid 27237208)
17. Mahner S, Baasch C, Schwarz J, Hein S, Wolber L, Janicke F, Milde- Langosch K (2008a) C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer 99(8):1269-1275
18. Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, Dose-Schwarz J (2008b) Comparison between positron emission tomography using 2-[Xuorine-18]Xuoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 19(7):1249-1254
19. Mahner S, Woelber L, Jung S, Eulenburg CZ, Ihnen M, Schwarz J, Sehouli J, Jaenicke F (2009) Prognostic signiWcance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction. Anticancer Res 29(7):2817-2821
20. Markman M (2009) PET/CT scans in ovarian cancer: prognostic versus predictive utility? Minerva Med 100(5):415-420
21. Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P (1995) Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 86(2):259-264
22. Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, Farias-Eisner R (2008) The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 199(3):215-223
23. Paramasivam S, Tripcony L, Crandon A, Quinn M, Hammond I, Marsden D, Proietto A, Davy M, Carter J, Nicklin J, Perrin L, Obermair A (2005) Prognostic importance of preoperative CA-125 in international federation of gynecology and obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol 23(25):5938-5942
24. Rossi AC, Di Vagno G, Cormio G, Cazzolla A, Stefanelli S, D'Elia E, Selvaggi L (2004) A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer. Arch Gynecol Obstet 269(4):263-265 (Pubitemid 38661265)
25. Shaaban A, Rezvani M (2009) Ovarian cancer: detection and radiologic staging. Clin Obstet Gynecol 52(1):73-93
26. Shih KK, Chi DS (2010) Maximal cytoreductive eVort in epithelial ovarian cancer surgery. J Gynecol Oncol 21(2):75-80
27. Vorgias G, Iavazzo C, Savvopoulos P, Myriokefalitaki E, Katsoulis M, Kalinoglou N, Akrivos T (2009) Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gynecol Oncol 112(1):11-15
28. Woelber L, Mueller V, Eulenburg C, Schwarz J, Carney W, Jaenicke F, Milde-Langosch K, Mahner S (2010) Serum carbonic anhydrase IX during Wrst-line therapy of ovarian cancer. Gynecol Oncol 117(2):183-188
29. Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK (2009) The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a gynecologic oncology group study. Cancer 115(5):1028-1035